Sorafenib exerts its anticancer activity by inhibiting tumor angiogenesis through signaling pathways involving vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) (5) and Raf/MEK/ERK signaling cascade (6). This evidence concerns the gene PDGFRB and neoplasm.